KRP 104
Alternative Names: KRP-104Latest Information Update: 02 Oct 2021
At a glance
- Originator ActivX Biosciences; Kyorin Pharmaceutical
- Developer Kyorin Pharmaceutical
- Class Antihyperglycaemics; Small molecules
- Mechanism of Action Dipeptidyl peptidase 4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Type 2 diabetes mellitus